Latest News & Features
Big Pharma
AstraZeneca has sued Taro Pharmaceuticals in two US federal courts alleging that Taro’s planned generic blood-thinning treatment infringes a patent for its Brilinta (ticagrelor) medication. 24 February 2022
Americas
Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents. 24 February 2022
Americas
The Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid. 22 February 2022
Americas
Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate). 22 February 2022
Americas
US Senator Elizabeth Warren has urged the Department of Health and Human Services (HHS) to seize control of patents covering Pfizer’s prostate cancer drug Xtandi (enzalutamide). 22 February 2022
Generics
Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires. 17 February 2022
Big Pharma
Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end. 17 February 2022
Americas
A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified. 17 February 2022
Generics
Afrigen Biologics has used the publicly available information relating to Moderna’s COVID-19 vaccine to manufacture its own version of the treatment, which could see testing by the end of this year. 15 February 2022
Medtech
The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board rulings that a Johnson & Johnson subsidiary’s patent is valid and infringed. 15 February 2022